These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 17063327

  • 1. Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat.
    Kuzumoto Y, Kusunoki S, Kato N, Kihara M, Low PA.
    Diabetologia; 2006 Dec; 49(12):3085-93. PubMed ID: 17063327
    [Abstract] [Full Text] [Related]

  • 2. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.
    Obrosova IG, Pacher P, Szabó C, Zsengeller Z, Hirooka H, Stevens MJ, Yorek MA.
    Diabetes; 2005 Jan; 54(1):234-42. PubMed ID: 15616034
    [Abstract] [Full Text] [Related]

  • 3. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
    Kato N, Mizuno K, Makino M, Suzuki T, Yagihashi S.
    Diabetes Res Clin Pract; 2000 Oct; 50(2):77-85. PubMed ID: 10960717
    [Abstract] [Full Text] [Related]

  • 4. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K, Kato N, Makino M, Suzuki T, Shindo M.
    J Diabetes Complications; 1999 Oct; 13(3):141-50. PubMed ID: 10509874
    [Abstract] [Full Text] [Related]

  • 5. Effect of fidarestat and alpha-lipoic acid on diabetes-induced epineurial arteriole vascular dysfunction.
    Yorek MA, Coppey LJ, Gellett JS, Davidson EP, Lund DD.
    Exp Diabesity Res; 2004 Oct; 5(2):123-35. PubMed ID: 15203883
    [Abstract] [Full Text] [Related]

  • 6. Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy.
    Stavniichuk R, Shevalye H, Hirooka H, Nadler JL, Obrosova IG.
    Biochem Pharmacol; 2012 Apr 01; 83(7):932-40. PubMed ID: 22285226
    [Abstract] [Full Text] [Related]

  • 7. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
    Hotta N, Kakuta H, Fukasawa H, Koh N, Sakakibara F, Nakamura J, Hamada Y, Wakao T, Hara T, Mori K.
    Diabetes Res Clin Pract; 1995 Feb 01; 27(2):107-17. PubMed ID: 7607048
    [Abstract] [Full Text] [Related]

  • 8. Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase.
    Price SA, Agthong S, Middlemas AB, Tomlinson DR.
    Diabetes; 2004 Jul 01; 53(7):1851-6. PubMed ID: 15220210
    [Abstract] [Full Text] [Related]

  • 9. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H, Tawata M, Aida K, Onaya T.
    J Clin Endocrinol Metab; 1992 Feb 01; 74(2):393-8. PubMed ID: 1370506
    [Abstract] [Full Text] [Related]

  • 10. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
    Cotter MA, Cameron NE, Hohman TC.
    J Peripher Nerv Syst; 1998 Feb 01; 3(3):217-23. PubMed ID: 10959252
    [Abstract] [Full Text] [Related]

  • 11. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy.
    Nagamatsu M, Nickander KK, Schmelzer JD, Raya A, Wittrock DA, Tritschler H, Low PA.
    Diabetes Care; 1995 Aug 01; 18(8):1160-7. PubMed ID: 7587852
    [Abstract] [Full Text] [Related]

  • 12. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat.
    Stevens MJ, Lattimer SA, Kamijo M, Van Huysen C, Sima AA, Greene DA.
    Diabetologia; 1993 Jul 01; 36(7):608-14. PubMed ID: 8359577
    [Abstract] [Full Text] [Related]

  • 13. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats.
    Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, Stevens MJ.
    Diabetes; 2003 Mar 01; 52(3):864-71. PubMed ID: 12606532
    [Abstract] [Full Text] [Related]

  • 14. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
    Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J, Sakamoto N, SNK-860 Diabetic Neuropathy Study Group.
    Diabetes Care; 2001 Oct 01; 24(10):1776-82. PubMed ID: 11574441
    [Abstract] [Full Text] [Related]

  • 15. The effects of zenarestat, an aldose reductase inhibitor, on minimal F-wave latency and nerve blood flow in streptozotocin-induced diabetic rats.
    Yamamoto T, Takakura S, Kawamura I, Seki J, Goto T.
    Life Sci; 2001 Feb 09; 68(12):1439-48. PubMed ID: 11388695
    [Abstract] [Full Text] [Related]

  • 16. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage.
    Ho EC, Lam KS, Chen YS, Yip JC, Arvindakshan M, Yamagishi S, Yagihashi S, Oates PJ, Ellery CA, Chung SS, Chung SK.
    Diabetes; 2006 Jul 09; 55(7):1946-53. PubMed ID: 16804062
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
    Sobajima H, Aoki T, Sassa H, Suzuki T, Taniko K, Makino M, Mizuno K, Suzuki T.
    Pharmacology; 2001 May 09; 62(4):193-9. PubMed ID: 11359994
    [Abstract] [Full Text] [Related]

  • 18. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
    Obrosova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ.
    FASEB J; 2002 Jan 09; 16(1):123-5. PubMed ID: 11709499
    [Abstract] [Full Text] [Related]

  • 19. Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo.
    Hattori T, Matsubara A, Taniguchi K, Ogura Y.
    Curr Eye Res; 2010 Feb 09; 35(2):146-54. PubMed ID: 20136425
    [Abstract] [Full Text] [Related]

  • 20. Transition metals and polyol pathway in the development of diabetic neuropathy in rats.
    Nakamura J, Hamada Y, Chaya S, Nakashima E, Naruse K, Kato K, Yasuda Y, Kamiya H, Sakakibara F, Koh N, Hotta N.
    Diabetes Metab Res Rev; 2002 Feb 09; 18(5):395-402. PubMed ID: 12397582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.